Literature DB >> 11220642

A cell wall component from pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-alpha, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat.

G M Wray1, S J Foster, C J Hinds, C Thiemermann.   

Abstract

The incidence of sepsis and septic shock due to gram-positive organisms has increased dramatically over the last two decades. Interestingly, many patients with sepsis/septic shock have both gram-positive and gram-negative bacteria present in the bloodstream and these polymicrobial or "mixed" infections often have a higher mortality than infection due to a single organism. The reason for this observation is unclear. The aim of this study was to investigate whether cell wall fragments from gram-positive and gram-negative bacteria could synergise to cause the release of cytokines, shock, and organ injury/ dysfunction in vivo. Male Wistar rats were anaesthetised and received an intravenous bolus of vehicle (saline), lipopolysaccharide (LPS) from Escherichia coli (0.1 mg/kg), peptidoglycan (Pep G) from Staphylococcus aureus (S10 mg/kg), co-administration of LPS (0.1 mg/kg) and PepG from S. aureus (10 mg/kg), LPS (10 mg/kg), PepG from Bacillus subtilis, or co-administration of LPS and PepG from B. subtilis. Blood pressure and heart rate were monitored for 6 h before plasma samples were taken for the measurement of TNF-alpha, total nitrite, and biochemical indices of organ injury. Peptidoglycan from both pathogenic (S. aureus) and non-pathogenic (B. subtilis) gram-positive bacteria synergised with endotoxin to cause formation of TNF-alpha, nitrite, shock, and organ injury. Synergism between PepG and LPS may partly explain the high mortality associated with mixed bacterial infections, as well as the deleterious effects of translocation of bacteria, or their cell wall components from the gut lumen in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220642     DOI: 10.1097/00024382-200115020-00010

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  29 in total

Review 1.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

2.  Monocyte procoagulant responses to anthrax peptidoglycan are reinforced by proinflammatory cytokine signaling.

Authors:  Narcis Ioan Popescu; Alanson Girton; Tarea Burgett; Kessa Lovelady; K Mark Coggeshall
Journal:  Blood Adv       Date:  2019-08-27

3.  Anti-peptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in Gram-positive sepsis.

Authors:  Dawei Sun; Brent Raisley; Marybeth Langer; Janaki K Iyer; Vidya Vedham; Jimmy L Ballard; Judith A James; Jordan Metcalf; K Mark Coggeshall
Journal:  J Immunol       Date:  2012-07-18       Impact factor: 5.422

4.  Effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on endothelial dysfunction, lipid peroxidation, and hepatocyte morphology in rats with sepsis-induced liver damage.

Authors:  Eray Kara; Ahmet Var; Seda Vatansever; Serap Cilaker; Yavuz Kaya; Teoman Coşkun
Journal:  Curr Ther Res Clin Exp       Date:  2004-05

5.  Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain.

Authors:  Anders E Myhre; Jon Fredrik Stuestøl; Maria K Dahle; Gunhild Øverland; Christoph Thiemermann; Simon J Foster; Per Lilleaasen; Ansgar O Aasen; Jacob E Wang
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

6.  Lipoteichoic acid and peptidoglycan from Staphylococcus aureus synergistically induce neutrophil influx into the lungs of mice.

Authors:  Jaklien C Leemans; Mirjam Heikens; Kok P M van Kessel; Sandrine Florquin; Tom van der Poll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

Review 7.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

8.  Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.

Authors:  Ping Qiu; Yan Li; Joseph Shiloach; Xizhong Cui; Junfeng Sun; Loc Trinh; Joanna Kubler-Kielb; Evgeny Vinogradov; Haresh Mani; Mariam Al-Hamad; Yvonne Fitz; Peter Q Eichacker
Journal:  J Infect Dis       Date:  2013-06-03       Impact factor: 5.226

9.  Bacillus anthracis peptidoglycan activates human platelets through FcγRII and complement.

Authors:  Dawei Sun; Narcis I Popescu; Brent Raisley; Ravi S Keshari; George L Dale; Florea Lupu; K Mark Coggeshall
Journal:  Blood       Date:  2013-06-03       Impact factor: 22.113

10.  Nonheart failure-associated elevation of amino terminal pro-brain natriuretic peptide in the setting of sepsis.

Authors:  Simona L Bar; Elizabeth Swiggum; Lynn Straatman; Andrew Ignaszewski
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.